Intercept Pharmaceuticals, Inc. (ICPT) reported fourth quarter EPS of ($1.63) before the opening bell Monday, compared to the consensus estimate of ($1.62). Revenues decreased 11.1% from last year to $0.04 million. Analysts expected revenues of $0.42 million.
For the full-year 2014, net loss attributable to common stockholders was $283.2 million, or $13.63 per share, compared to a net loss of $67.8 million, or $3.76 per share, for the full year 2013. For year 2015, Intercept projects adjusted operating expenses in the range of $180 to $200 million, excluding stock-based compensation and other non-cash items.
On valuation measures, Intercept Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 552,630 shares, print a return on assets and return on equity of (25.83%) and (148.15%), respectively. The median Wall Street price target on the name is $440.00. Currently ticker boasts 10 ‘Buy’ endorsements, compared to 2 ’Holds’ and 1 ‘Sell’.
Profitability-wise, ICPT has a t-12 operating margin of (5,403%). The $4.73 billion market cap company reported $239.7 million in cash vs. $0 in debt in its most recent quarter.
ICPT currently prints a one year loss of about 48% and a year-to-date return of around 42%.
The chart below shows where the equity has traded over the last 52 weeks.
Intercept Pharmaceuticals Inc. is a development stage biopharmaceutical firm with a focus on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases. The company was founded in 2002 and is headquartered in New York.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!